行情

CPRX

CPRX

触媒制药公司
NASDAQ

实时行情|Nasdaq Last Sale

4.300
-0.260
-5.70%
盘后: 4.310 +0.01 +0.23% 17:50 12/11 EST
开盘
4.540
昨收
4.560
最高
4.550
最低
4.240
成交量
252.56万
成交额
--
52周最高
7.67
52周最低
1.850
市值
4.43亿
市盈率(TTM)
51.56
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CPRX 新闻

  • Catalyst Pharmaceuticals: A Potential Double In 2020
  • Seeking Alpha - Article.2天前
  • Edited Transcript of CPRX earnings conference call or presentation 13-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.12/05 01:35
  • Catalyst Focuses on Firdapse Label Expansion Amid Competition
  • Zacks.11/29 14:39
  • Catalyst Pharmaceuticals Option Alert: Jun 19 $7.5 Calls Sweep (25) near the Ask: 664 @ $0.651 vs 45 OI; Ref=$4.75
  • Benzinga.11/27 19:48

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CPRX 简况

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
展开

Webull提供Catalyst Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。